The estimated Net Worth of John A Paganelli is at least $753 Thousand dollars as of 5 January 2024. Mr. Paganelli owns over 25,000 units of Opko Health Inc stock worth over $599,570 and over the last 18 years he sold OPK stock worth over $97,350. In addition, he makes $56,000 as Independent Director at Opko Health Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Paganelli OPK stock SEC Form 4 insiders trading
John has made over 20 trades of the Opko Health Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of OPK stock worth $22,000 on 5 January 2024.
The largest trade he's ever made was exercising 100,000 units of Opko Health Inc stock on 10 March 2014 worth over $236,000. On average, John trades about 9,369 units every 132 days since 2007. As of 5 January 2024 he still owns at least 384,340 units of Opko Health Inc stock.
You can see the complete history of Mr. Paganelli stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Paganelli biography
John A. Paganelli serves as Independent Director of the Company. Mr. Paganelli has served as a director of the Company since December 2003. Mr. Paganelli served as the Company’s Interim Chief Executive Officer and Secretary from June 29, 2005 through March 27, 2007, the Company’s Interim Chief Financial Officer from June 29, 2005 through July 1, 2005, and Chairman of our Board from December 2003 through March 27, 2007. Mr. Paganelli served as President and Chief Executive Officer of Transamerica Life Insurance Company of New York from 1992 to 1997. Since 1987, Mr. Paganelli has been a partner in RFG Associates, a financial planning organization. Mr. Paganelli is also the Managing Partner of Pharos Systems Partners, LLC, an investment company, and he is Chairman of the Board of Pharos Systems International, a software company. He was Vice President and Executive Vice President of PEG Capital Management, an investment advisory organization, from 1987 until 2000. Mr. Paganelli also serves as a director of Western New York Energy, LLC and is on the Board of Trustees of Paul Smith’s College. With his significant experience in investment management and operations, Mr. Paganelli is able to add valuable expertise and insight to our Board on a wide range of operational and financial issues. As one of the longest tenured members of our Board, he also has substantial knowledge and familiarity regarding our historical operations.
What is the salary of John Paganelli?
As the Independent Director of Opko Health Inc, the total compensation of John Paganelli at Opko Health Inc is $56,000. There are 9 executives at Opko Health Inc getting paid more, with Phillip Frost having the highest compensation of $1,405,200.
How old is John Paganelli?
John Paganelli is 85, he's been the Independent Director of Opko Health Inc since 2007. There are no older and 20 younger executives at Opko Health Inc.
What's John Paganelli's mailing address?
John's mailing address filed with the SEC is OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI, FL, 33137.
Insiders trading at Opko Health Inc
Over the last 18 years, insiders at Opko Health Inc have traded over $862,245 worth of Opko Health Inc stock and bought 128,867,460 units worth $425,265,065 . The most active insiders traders include Phillip Md Et Al Frost Neva..., Phillip Md Et Al Frost Gamm..., and Phillip Md Et Al Frost Gamm.... On average, Opko Health Inc executives and independent directors trade stock every 4 days with the average trade being worth of $142,696. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 23 May 2024, trading 100,000 units of OPK stock currently worth $127,000.
What does Opko Health Inc do?
opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig
What does Opko Health Inc's logo look like?
Complete history of Mr. Paganelli stock trades at Opko Health Inc
Opko Health Inc executives and stock owners
Opko Health Inc executives and other stock owners filed with the SEC include:
-
Phillip Frost,
Chairman of the Board, Chief Executive Officer -
Jane Hsiao,
Vice Chairman of the Board, Chief Technical Officer -
Steven Rubin,
Executive Vice President - Administration, Director -
Adam E. Logal,
Sr. VP & CFO -
Dr. Phillip Frost Ph.D.,
Chairman & CEO -
Adam Logal,
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer -
Dr. Jane H. Hsiao M.B.A., MBA, Ph.D.,
Vice Chairman & Chief Technical Officer -
Steven D. Rubin Esq., J.D.,
Exec. VP of Admin. & Director -
Richard Pfenniger,
Independent Director -
John Paganelli,
Independent Director -
Richard Krasno,
Independent Director -
Richard Lerner,
Independent Director -
Robert Fishel,
Independent Director -
Alice Yu,
Independent Director -
Yvonne Briggs,
Investor Relations -
Anthony Japour,
Independent Director -
Geoff Monk,
President of BioReference Laboratories -
Tony Cruz,
Chief Executive Officer, Transition Therapeutics, Inc -
Charles Bishop,
Chief Executive Officer of OPKO Renal -
Jon Cohen,
Director, Executive Chairman of BioReference Laboratories -
Dr. David Okrongly Ph.D.,
Pres of OPKO Diagnostics -
Jane Pine Wood Esq., J.D.,
Chief Legal Officer of Bio-Reference Laboratories -
Dr. Akhtar Ashfaq,
Sr. VP of Clinical R&D and Medical Affairs -
James DeMarco,
Sr. VP of Pharmaceutical Sales -
Dr. Arie Gutman,
Pres of API -
Alexis Borisy,
Director -
Phillip Md Et Al Frost Gamm...,
CEO & Chairman -
Gary J. Nabel,
Chief Innovation Officer -
Phillip Md Et Al Frost Neva...,
CEO & Chairman -
Phillip Md Et Al Frost,
CEO & Chairman -
Roger Md Medel,
-
Prem A Lachman,
-
Gamma Investment Trust Frost,
10% owner -
Subbarao V Uppaluri,
Senior VP- CFO -
Thomas E Beier,
Director -
Robert A Baron,
Director -
Michael Reich,
Director -
David A Eichler,
Director -
Dmitry Kolosov,
Director -
Md Pascal J Goldschmidt,,
Director -
Elias A. Zerhouni,
Vice Chairman and President